Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers

Summary Background  Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transpl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of dermatology (1951) 2011-07, Vol.165 (1), p.144-151
Hauptverfasser: Bagazgoitia, L., Cuevas Santos, J., Juarranz, Á., Jaén, P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 151
container_issue 1
container_start_page 144
container_title British journal of dermatology (1951)
container_volume 165
creator Bagazgoitia, L.
Cuevas Santos, J.
Juarranz, Á.
Jaén, P.
description Summary Background  Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients. Objectives  To describe the molecular and genetic changes underlying this preventive effect. Methods  Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out. Results  Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable. Conclusions  These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.
doi_str_mv 10.1111/j.1365-2133.2011.10270.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_907161932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907161932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4200-f3daa682a3d03c78a053f139fe373ed8cabfeee65899bfb8adfa272ff596e1f93</originalsourceid><addsrcrecordid>eNpFkU-P0zAQxS0EYrsLXwHlgjgljD3NvwsS7LILaAVIgDhaU2fcpiRxN06g-fY4bSm-2Nb7zdPoPSEiCYkM5_U2kZilsZKIiQIpEwkqh2T_SCzOwmOxAIA8hjLDC3Hp_RZAIqTwVFwomck0l9lC_P66cYOrpo7a2kTDhnvaTVHP1WjYz_9oU_vBNW5dG2oiyzSMfVCcjcgMdReGKmppzRF11YHn_S4AvnbdDDH1zRS5zrg1z3BL_S_u_TPxxFLj-fnpvhI_bt9_v_4Q33-5-3j99j42SwUQW6yIskIRVoAmLwhStBJLy5gjV4WhlWXmLC3KcmVXBVWWVK6sTcuMpS3xSrw6-u569zCyH3Rbe8NNQx270esSQgqyRBXIFydyXLVc6V1fh10n_S-qALw8AeRDFLanztT-P7dELLHAwL05cn_qhqezLkHP1emtnhvSc0N6rk4fqtN7_e7TzeEZDOKjQQie92eDEJzOcsxT_fPzXRj9VtyoJegC_wK9fZ2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>907161932</pqid></control><display><type>article</type><title>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Wiley Online Library All Journals</source><creator>Bagazgoitia, L. ; Cuevas Santos, J. ; Juarranz, Á. ; Jaén, P.</creator><creatorcontrib>Bagazgoitia, L. ; Cuevas Santos, J. ; Juarranz, Á. ; Jaén, P.</creatorcontrib><description>Summary Background  Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients. Objectives  To describe the molecular and genetic changes underlying this preventive effect. Methods  Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out. Results  Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable. Conclusions  These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/j.1365-2133.2011.10270.x</identifier><identifier>PMID: 21615716</identifier><identifier>CODEN: BJDEAZ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; Aminolevulinic Acid - analogs &amp; derivatives ; Aminolevulinic Acid - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Biopsy ; Carcinogenesis ; Cyclin D - metabolism ; cyclin D1 ; Dermatology ; Dysplasia ; Female ; Humans ; Immunohistochemistry ; Keratosis ; Keratosis, Actinic - drug therapy ; Keratosis, Actinic - metabolism ; Keratosis, Actinic - pathology ; Ki-67 Antigen - metabolism ; Light effects ; Male ; Medical sciences ; Middle Aged ; p53 protein ; Photochemotherapy - methods ; photodynamic therapy ; Photosensitizing Agents - therapeutic use ; Skin cancer ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>British journal of dermatology (1951), 2011-07, Vol.165 (1), p.144-151</ispartof><rights>2011 The Authors. BJD © 2011 British Association of Dermatologists 2011</rights><rights>2015 INIST-CNRS</rights><rights>2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4200-f3daa682a3d03c78a053f139fe373ed8cabfeee65899bfb8adfa272ff596e1f93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2133.2011.10270.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2133.2011.10270.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24339383$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21615716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bagazgoitia, L.</creatorcontrib><creatorcontrib>Cuevas Santos, J.</creatorcontrib><creatorcontrib>Juarranz, Á.</creatorcontrib><creatorcontrib>Jaén, P.</creatorcontrib><title>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Summary Background  Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients. Objectives  To describe the molecular and genetic changes underlying this preventive effect. Methods  Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out. Results  Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable. Conclusions  These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aminolevulinic Acid - analogs &amp; derivatives</subject><subject>Aminolevulinic Acid - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biopsy</subject><subject>Carcinogenesis</subject><subject>Cyclin D - metabolism</subject><subject>cyclin D1</subject><subject>Dermatology</subject><subject>Dysplasia</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Keratosis</subject><subject>Keratosis, Actinic - drug therapy</subject><subject>Keratosis, Actinic - metabolism</subject><subject>Keratosis, Actinic - pathology</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Light effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>p53 protein</subject><subject>Photochemotherapy - methods</subject><subject>photodynamic therapy</subject><subject>Photosensitizing Agents - therapeutic use</subject><subject>Skin cancer</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU-P0zAQxS0EYrsLXwHlgjgljD3NvwsS7LILaAVIgDhaU2fcpiRxN06g-fY4bSm-2Nb7zdPoPSEiCYkM5_U2kZilsZKIiQIpEwkqh2T_SCzOwmOxAIA8hjLDC3Hp_RZAIqTwVFwomck0l9lC_P66cYOrpo7a2kTDhnvaTVHP1WjYz_9oU_vBNW5dG2oiyzSMfVCcjcgMdReGKmppzRF11YHn_S4AvnbdDDH1zRS5zrg1z3BL_S_u_TPxxFLj-fnpvhI_bt9_v_4Q33-5-3j99j42SwUQW6yIskIRVoAmLwhStBJLy5gjV4WhlWXmLC3KcmVXBVWWVK6sTcuMpS3xSrw6-u569zCyH3Rbe8NNQx270esSQgqyRBXIFydyXLVc6V1fh10n_S-qALw8AeRDFLanztT-P7dELLHAwL05cn_qhqezLkHP1emtnhvSc0N6rk4fqtN7_e7TzeEZDOKjQQie92eDEJzOcsxT_fPzXRj9VtyoJegC_wK9fZ2w</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Bagazgoitia, L.</creator><creator>Cuevas Santos, J.</creator><creator>Juarranz, Á.</creator><creator>Jaén, P.</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>201107</creationdate><title>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</title><author>Bagazgoitia, L. ; Cuevas Santos, J. ; Juarranz, Á. ; Jaén, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4200-f3daa682a3d03c78a053f139fe373ed8cabfeee65899bfb8adfa272ff596e1f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aminolevulinic Acid - analogs &amp; derivatives</topic><topic>Aminolevulinic Acid - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biopsy</topic><topic>Carcinogenesis</topic><topic>Cyclin D - metabolism</topic><topic>cyclin D1</topic><topic>Dermatology</topic><topic>Dysplasia</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Keratosis</topic><topic>Keratosis, Actinic - drug therapy</topic><topic>Keratosis, Actinic - metabolism</topic><topic>Keratosis, Actinic - pathology</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Light effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>p53 protein</topic><topic>Photochemotherapy - methods</topic><topic>photodynamic therapy</topic><topic>Photosensitizing Agents - therapeutic use</topic><topic>Skin cancer</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bagazgoitia, L.</creatorcontrib><creatorcontrib>Cuevas Santos, J.</creatorcontrib><creatorcontrib>Juarranz, Á.</creatorcontrib><creatorcontrib>Jaén, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bagazgoitia, L.</au><au>Cuevas Santos, J.</au><au>Juarranz, Á.</au><au>Jaén, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2011-07</date><risdate>2011</risdate><volume>165</volume><issue>1</issue><spage>144</spage><epage>151</epage><pages>144-151</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><coden>BJDEAZ</coden><abstract>Summary Background  Photodynamic therapy (PDT) has been shown to be effective in treating nonmelanoma skin cancer (NMSC), especially actinic keratosis (AK). Moreover, there is sufficient evidence of its effectiveness in preventing the appearance of premalignant and malignant lesions in organ transplant recipients. Objectives  To describe the molecular and genetic changes underlying this preventive effect. Methods  Twenty‐two patients with AK were treated with methyl aminolaevulinate and red light. Biopsies were performed before and 6 weeks after the treatment. Conventional histopathology and immunohistochemistry were carried out. Results  Not only was a reduction in the dysplasia and elastosis observed, but also a decreased expression of Ki‐67 and p53. The abnormal findings did not disappear completely in all cases. The expression of cyclin D1 remained stable. Conclusions  These findings show that PDT has the potential to reduce the histological signs of photoageing. Moreover, the reduction of Ki‐67, a marker of proliferation and of p53, a marker of early skin carcinogenesis, indicates a reversal of the carcinogenic process. On the other hand, the fact that one treatment does not clear dysplasia and expression of p53 completely, and the persistence of cyclin D1, indicate that one single treatment, despite showing good clinical results, is not sufficient to clear completely the signs of chronic actinic damage, and thus the risk of NMSC.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21615716</pmid><doi>10.1111/j.1365-2133.2011.10270.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0007-0963
ispartof British journal of dermatology (1951), 2011-07, Vol.165 (1), p.144-151
issn 0007-0963
1365-2133
language eng
recordid cdi_proquest_miscellaneous_907161932
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Wiley Online Library All Journals
subjects Aged
Aged, 80 and over
Aminolevulinic Acid - analogs & derivatives
Aminolevulinic Acid - therapeutic use
Biological and medical sciences
Biomarkers, Tumor - metabolism
Biopsy
Carcinogenesis
Cyclin D - metabolism
cyclin D1
Dermatology
Dysplasia
Female
Humans
Immunohistochemistry
Keratosis
Keratosis, Actinic - drug therapy
Keratosis, Actinic - metabolism
Keratosis, Actinic - pathology
Ki-67 Antigen - metabolism
Light effects
Male
Medical sciences
Middle Aged
p53 protein
Photochemotherapy - methods
photodynamic therapy
Photosensitizing Agents - therapeutic use
Skin cancer
Tumor Suppressor Protein p53 - metabolism
title Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T13%3A27%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Photodynamic%20therapy%20reduces%20the%20histological%20features%20of%20actinic%20damage%20and%20the%20expression%20of%20early%20oncogenic%20markers&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Bagazgoitia,%20L.&rft.date=2011-07&rft.volume=165&rft.issue=1&rft.spage=144&rft.epage=151&rft.pages=144-151&rft.issn=0007-0963&rft.eissn=1365-2133&rft.coden=BJDEAZ&rft_id=info:doi/10.1111/j.1365-2133.2011.10270.x&rft_dat=%3Cproquest_pubme%3E907161932%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=907161932&rft_id=info:pmid/21615716&rfr_iscdi=true